Dr. Lal Path Labs Ltd.
LALPATHLABHealthcare filings
We hold this company’s filings and have not read the financial statements out of them yet. Every filing on record is listed under filings, and each one opens.
Earnings calls
29 transcript(s)/analyst meet(s) served; 0 document(s) on file are not transcripts (cover letters, duplicates, unresolved) and are excluded. Speaker attribution is shown only where the segmenter attributes ≥ 95% of sentences to management or analysts (0 of 29 documents here); elsewhere sentences render unattributed.
| Kind | Date | Period | Served | Attribution rate |
|---|---|---|---|---|
| TRANSCRIPT | 20190307 | 2018-12-31 | yes | |
| TRANSCRIPT | 20190619 | 2019-03-31 | yes | |
| TRANSCRIPT | 20190828 | 2019-06-30 | yes | |
| TRANSCRIPT | 20190829 | 2019-06-30 | yes | |
| TRANSCRIPT | 20200609 | 2020-03-31 | yes | |
| TRANSCRIPT | 20200817 | 2020-06-30 | yes | |
| TRANSCRIPT | 20201124 | 2020-09-30 | yes | |
| TRANSCRIPT | 20210209 | 2020-12-31 | yes | |
| TRANSCRIPT | 20210608 | 2021-03-31 | yes | |
| TRANSCRIPT | 20210811 | 2021-06-30 | yes | |
| TRANSCRIPT | 20211115 | 2021-09-30 | yes | |
| TRANSCRIPT | 20220225 | 2021-12-31 | yes | |
| TRANSCRIPT | 20220523 | 2022-03-31 | yes | |
| TRANSCRIPT | 20220803 | 2022-06-30 | yes | |
| TRANSCRIPT | 20221114 | 2022-09-30 | yes | |
| TRANSCRIPT | 20230208 | 2022-12-31 | yes | |
| TRANSCRIPT | 20230516 | 2023-03-31 | yes | |
| TRANSCRIPT | 20230802 | 2023-06-30 | yes | |
| TRANSCRIPT | 20231108 | 2023-09-30 | yes | |
| TRANSCRIPT | 20240207 | 2023-12-31 | yes | |
| TRANSCRIPT | 20240515 | 2024-03-31 | yes | |
| TRANSCRIPT | 20240813 | 2024-06-30 | yes | |
| TRANSCRIPT | 20241028 | 2024-09-30 | yes | |
| TRANSCRIPT | 20250203 | 2024-12-31 | yes | |
| TRANSCRIPT | 20250501 | 2025-03-31 | yes | |
| TRANSCRIPT | 20250805 | 2025-06-30 | yes | |
| TRANSCRIPT | 20251106 | 2025-09-30 | yes | |
| TRANSCRIPT | 20260203 | 2025-12-31 | yes | |
| TRANSCRIPT | 20260730 | 2026-06-30 | yes |
LALPATHLAB
files the standard Schedule III statements. Every figure below opens to the filing it was read from; where a figure is not shown, the reason is printed in its place.
Identity
| Statement division | general |
| Scope served | consolidated |
| Panels on this page | 4 |
Market
The closes are adjusted for every split and bonus on record inside the period this series covers, and each adjustment is checked against the price move on its ex-date.
| Last close | 1,961.30 |
| 52-week range | 1307.6 – 1968.4 |
| Return 1M | 2.49% |
| Return 3M | 16.11% |
| Return 1Y | 18.71% |
| Return 3Y | 64.4% |
| Return 5Y | 0.85% |
| Market capitalisation | not shown — we could not confirm it |
| Shares outstanding | not shown — we could not confirm it |
| P/E | not shown — we could not confirm it |
| P/B | not shown — we could not confirm it |
| EV/EBITDA | not shown — we could not confirm it |
Latest quarter filed — period ending 2026-06-30
In INR crore except per-share figures. `period_id` is the period the filing names for the number; the date beside each cell is when it was filed.
| Revenue from operations | 798.00 |
| Other income | 32.00 |
| Total income | 830.00 |
| Cost of materials consumed | 152.00 |
| Purchases of stock-in-trade | 0.00 |
| Changes in inventories | 0.00 |
| Employee benefit expense | 133.00 |
| Finance costs | 6.00 |
Ownership — 2026-06-30, and the change from 2026-03-31
| Holder | Per cent | Change |
|---|---|---|
| promoter and promoter group | 0.53 | -0.00 |
| institutions foreign | 0.17 | 0.00 |
| institutions domestic | 0.22 | 0.00 |
| mutual funds | 0.19 | 0.00 |
| public | 0.46 | -0.00 |
Documents on file
| Class | Most recent | On file |
|---|---|---|
| TRANSCRIPT | 2026-06-30 | 29 |
Financial statements
Filed results, consolidated, in INR crore except per-share figures. Every figure opens to the filing it was read from. Quarterly and annual columns are the periods the filing itself names, never a document date.
Quarterly results, as filed
| Line | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 534.00 | 489.00 | 491.00 | 541.00 | 601.00 | 539.00 | 545.00 | 602.00 | 660.00 | 597.00 | 603.00 | 670.00 | 731.00 | 660.00 | 703.00 | 798.00 |
| Other income | 9.00 | 10.00 | 14.00 | 14.00 | 18.00 | 18.00 | 18.00 | 21.00 | 22.00 | 25.00 | 26.00 | 28.00 | 25.00 | 24.00 | 24.00 | 32.00 |
| Total income | 542.00 | 500.00 | 505.00 | 555.00 | 619.00 | 557.00 | 564.00 | 622.00 | 682.00 | 622.00 | 628.00 | 698.00 | 755.00 | 684.00 | 727.00 | 830.00 |
| Cost of materials consumed | 116.00 | 111.00 | 106.00 | 113.00 | 122.00 | 107.00 | 109.00 | 119.00 | 127.00 | 117.00 | 118.00 | 129.00 | 142.00 | 129.00 | 135.00 | 152.00 |
| Purchases of stock-in-trade | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Employee benefit expense | 91.00 | 96.00 | 92.00 | 105.00 | 105.00 | 109.00 | 105.00 | 117.00 | 124.00 | 126.00 | 115.00 | 132.00 | 132.00 | 134.00 | 129.00 | 133.00 |
| Finance costs | 11.00 | 9.00 | 9.00 | 8.00 | 8.00 | 7.00 | 7.00 | 6.00 | 6.00 | 5.00 | 5.00 | 5.00 | 5.00 | 7.00 | 6.00 | 6.00 |
| Depreciation and amortisation | 39.00 | 38.00 | 38.00 | 35.00 | 36.00 | 36.00 | 37.00 | 35.00 | 35.00 | 36.00 | 36.00 | 35.00 | 40.00 | 42.00 | 45.00 | 44.00 |
| Other expenses | 183.00 | 169.00 | 177.00 | 177.00 | 196.00 | 182.00 | 186.00 | 196.00 | 206.00 | 199.00 | 200.00 | 216.00 | 232.00 | 217.00 | 252.00 | 266.00 |
| Total expenses | 440.00 | 423.00 | 422.00 | 438.00 | 467.00 | 441.00 | 444.00 | 473.00 | 499.00 | 484.00 | 475.00 | 517.00 | 552.00 | 530.00 | 567.00 | 601.00 |
| Profit before exceptional items and tax | 103.00 | 76.00 | 83.00 | 118.00 | 152.00 | 116.00 | 120.00 | 150.00 | 183.00 | 138.00 | 153.00 | 181.00 | 204.00 | 154.00 | 160.00 | 229.00 |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -30.00 | 0.00 | 0.00 |
| Profit before tax | 103.00 | 76.00 | 83.00 | 118.00 | 152.00 | 116.00 | 120.00 | 150.00 | 183.00 | 138.00 | 153.00 | 181.00 | 204.00 | 124.00 | 160.00 | 229.00 |
| Current tax | 37.00 | 23.00 | 23.00 | 38.00 | 43.00 | 34.00 | 33.00 | 45.00 | 48.00 | 40.00 | 39.00 | 45.00 | 47.00 | 40.00 | 27.00 | 60.00 |
| Deferred tax | -7.00 | 0.00 | 3.00 | -4.00 | -2.00 | -1.00 | 2.00 | -3.00 | 4.00 | 1.00 | -41.00 | 2.00 | 4.00 | -7.00 | 0.00 | -2.00 |
| Tax expense | 30.00 | 23.00 | 26.00 | 34.00 | 42.00 | 34.00 | 34.00 | 42.00 | 52.00 | 40.00 | -2.00 | 47.00 | 51.00 | 33.00 | 28.00 | 58.00 |
| Profit for the period | 72.00 | 54.00 | 57.00 | 84.00 | 111.00 | 82.00 | 86.00 | 108.00 | 131.00 | 98.00 | 156.00 | 134.00 | 152.00 | 91.00 | 132.00 | 170.00 |
| Profit attributable to owners | 72.00 | 53.00 | 57.00 | 83.00 | 109.00 | 81.00 | 84.00 | 106.00 | 129.00 | 97.00 | 155.00 | 132.00 | 151.00 | 90.00 | 131.00 | 170.00 |
| Profit attributable to non-controlling interests | 1.00 | 1.00 | 0.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 2.00 | 1.00 | 1.00 | 2.00 | 2.00 | 1.00 | 1.00 | 1.00 |
| Other comprehensive income | 3.00 | 1.00 | -2.00 | 0.00 | -0.00 | 0.00 | -1.00 | -0.00 | -1.00 | -0.00 | -3.00 | -1.00 | 2.00 | 0.00 | 4.00 | 1.00 |
| Total comprehensive income | 75.00 | 55.00 | 55.00 | 84.00 | 111.00 | 82.00 | 85.00 | 108.00 | 130.00 | 98.00 | 153.00 | 133.00 | 154.00 | 92.00 | 136.00 | 172.00 |
| Earnings per share, basic | 8.64 | 6.37 | 6.84 | 9.95 | 13.16 | 9.77 | 10.13 | 12.79 | 15.52 | 11.60 | 18.57 | 15.88 | 18.05 | 5.42 | 7.86 | 10.15 |
| Earnings per share, diluted | 8.60 | 6.35 | 6.82 | 9.93 | 13.12 | 9.76 | 10.12 | 12.76 | 15.48 | 11.58 | 18.54 | 15.85 | 18.01 | 5.41 | 7.85 | 10.13 |
Annual results, as filed
| Line | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 1,203.00 | 1,330.00 | 1,581.00 | 2,087.00 | 2,017.00 | 2,227.00 | 2,461.00 | 2,763.00 |
| Other income | 46.00 | 55.00 | 51.00 | 52.00 | 42.00 | 69.00 | 93.00 | 101.00 |
| Total income | 1,249.00 | 1,385.00 | 1,633.00 | 2,140.00 | 2,059.00 | 2,296.00 | 2,555.00 | 2,864.00 |
| Cost of materials consumed | 262.00 | 299.00 | 397.00 | 502.00 | 447.00 | 451.00 | 482.00 | 535.00 |
| Purchases of stock-in-trade | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Employee benefit expense | 208.00 | 243.00 | 274.00 | 365.00 | 376.00 | 424.00 | 482.00 | 503.00 |
| Finance costs | 1.00 | 15.00 | 16.00 | 30.00 | 38.00 | 29.00 | 22.00 | 23.00 |
| Depreciation and amortisation | 38.00 | 73.00 | 77.00 | 108.00 | 150.00 | 144.00 | 142.00 | 162.00 |
| Other expenses | 439.00 | 446.00 | 474.00 | 660.00 | 703.00 | 741.00 | 802.00 | 942.00 |
| Total expenses | 949.00 | 1,075.00 | 1,238.00 | 1,665.00 | 1,715.00 | 1,790.00 | 1,930.00 | 2,165.00 |
| Profit before exceptional items and tax | 301.00 | 310.00 | 394.00 | 475.00 | 344.00 | 506.00 | 625.00 | 699.00 |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -30.00 |
| Profit before tax | 301.00 | 310.00 | 394.00 | 475.00 | 344.00 | 506.00 | 625.00 | 669.00 |
| Current tax | 104.00 | 84.00 | 102.00 | 126.00 | 108.00 | 148.00 | 172.00 | 159.00 |
| Deferred tax | -4.00 | -1.00 | -4.00 | -2.00 | -5.00 | -5.00 | -40.00 | 0.00 |
| Tax expense | 100.00 | 83.00 | 98.00 | 125.00 | 103.00 | 143.00 | 132.00 | 159.00 |
| Profit for the period | 200.00 | 228.00 | 296.00 | 350.00 | 241.00 | 362.00 | 492.00 | 510.00 |
| Profit attributable to owners | 199.00 | 226.00 | 292.00 | 345.00 | 239.00 | 358.00 | 487.00 | 505.00 |
| Profit attributable to non-controlling interests | 1.00 | 2.00 | 5.00 | 6.00 | 2.00 | 5.00 | 5.00 | 5.00 |
| Other comprehensive income | -2.00 | -1.00 | -1.00 | -1.00 | 2.00 | -1.00 | -4.00 | 5.00 |
| Total comprehensive income | 198.00 | 226.00 | 296.00 | 349.00 | 243.00 | 362.00 | 489.00 | 515.00 |
| Earnings per share, basic | 24.19 | 27.42 | 35.33 | 41.70 | 28.82 | 43.05 | 58.48 | 30.24 |
| Earnings per share, diluted | 24.15 | 27.37 | 35.25 | 41.57 | 28.74 | 42.98 | 58.40 | 30.20 |
Balance sheet, as filed
| Line | 2022-09-30 | 2023-03-31 | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 2,302.00 | 2,386.00 | 2,445.00 | 2,456.00 | 2,598.00 | 2,717.00 | 2,959.00 | 3,146.00 |
| Non-current assets | 1,467.00 | 1,412.00 | 1,366.00 | 1,329.00 | 1,272.00 | 1,353.00 | 1,440.00 | 1,579.00 |
| Current assets | 835.00 | 973.00 | 1,079.00 | 1,127.00 | 1,326.00 | 1,364.00 | 1,520.00 | 1,567.00 |
| Property, plant and equipment | 416.00 | 401.00 | 347.00 | 343.00 | 328.00 | 336.00 | 429.00 | 484.00 |
| Capital work-in-progress | 7.00 | 3.00 | 10.00 | 4.00 | 1.00 | 4.00 | 17.00 | 6.00 |
| Goodwill | 555.00 | 548.00 | 548.00 | 548.00 | 548.00 | 548.00 | 548.00 | 548.00 |
| Other intangible assets | 381.00 | 356.00 | 329.00 | 303.00 | 279.00 | 251.00 | 221.00 | 192.00 |
| Inventories | 54.00 | 34.00 | 41.00 | 37.00 | 47.00 | 36.00 | 50.00 | 44.00 |
| Trade receivables | 92.00 | 71.00 | 86.00 | 77.00 | 90.00 | 88.00 | 101.00 | 111.00 |
| Cash and cash equivalents | 51.00 | 264.00 | 120.00 | 361.00 | 107.00 | 293.00 | 116.00 | 243.00 |
| Total equity and liabilities | 2,302.00 | 2,386.00 | 2,445.00 | 2,456.00 | 2,598.00 | 2,717.00 | 2,959.00 | 3,146.00 |
| Equity | 1,583.00 | 1,700.00 | 1,806.00 | 1,885.00 | 2,035.00 | 2,206.00 | 2,422.00 | 2,541.00 |
| Equity share capital | 83.00 | 83.00 | 84.00 | 84.00 | 84.00 | 84.00 | 84.00 | 168.00 |
| Other equity | 1,466.00 | 1,583.00 | 1,689.00 | 1,766.00 | 1,918.00 | 2,089.00 | 2,304.00 | 2,341.00 |
| Total liabilities | 719.00 | 686.00 | 639.00 | 571.00 | 562.00 | 510.00 | 537.00 | 605.00 |
| Non-current liabilities | 269.00 | 216.00 | 168.00 | 105.00 | 100.00 | 108.00 | 104.00 | 154.00 |
| Current liabilities | 450.00 | 470.00 | 471.00 | 465.00 | 462.00 | 402.00 | 433.00 | 451.00 |
| Borrowings, non-current | 125.00 | 83.00 | 42.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Borrowings, current | 112.00 | 153.00 | 83.00 | 83.00 | 42.00 | 0.00 | 0.00 | 0.00 |
| Trade payables | 169.00 | 156.00 | 194.00 | 187.00 | 212.00 | 199.00 | 191.00 | 181.00 |
Cash flow, as filed
| Line | 2022-09-30 | 2023-03-31 | 2023-09-30 | 2024-03-31 | 2024-09-30 | 2025-03-31 | 2025-09-30 | 2026-03-31 |
|---|---|---|---|---|---|---|---|---|
| Net cash from operating activities | 242.00 | 456.00 | 305.00 | 535.00 | 307.00 | 569.00 | 324.00 | 636.00 |
| Net cash from investing activities | -321.00 | -287.00 | -205.00 | -24.00 | -391.00 | -303.00 | -388.00 | -422.00 |
| Net cash from financing activities | -248.00 | -283.00 | -244.00 | -414.00 | -170.00 | -334.00 | -112.00 | -264.00 |
| Purchase of property, plant and equipment | 27.00 | 36.00 | 25.00 | 51.00 | 11.00 | 44.00 | 134.00 | 167.00 |
| Net increase in cash | -327.00 | -114.00 | -144.00 | 97.00 | -254.00 | -68.00 | -176.00 | -50.00 |
| con:CFO.BEFORE_TAX | 296.00 | 562.00 | 362.00 | 667.00 | 375.00 | 733.00 | 407.00 | 811.00 |
| con:INTEREST_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INTEREST_PAID.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:DIVIDENDS_RECEIVED.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:TAX_PAID.OPERATING | 54.00 | 106.00 | 56.00 | 132.00 | 68.00 | 164.00 | 83.00 | 175.00 |
| con:CF_OTHER.OPERATING | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INVESTMENTS_PURCHASED | 208.00 | 18.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:INVESTMENTS_SOLD | 151.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:PPE_DISPOSALS | 0.00 | 0.00 | 1.00 | 1.00 | 0.00 | 1.00 | 0.00 | 0.00 |
| con:CF_INVESTING.SUBSIDIARIES_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.SUBSIDIARIES_ACQUIRED | 18.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.JV_SOLD | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| con:CF_INVESTING.JV_ACQUIRED | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Who owns it
The shareholding pattern filed with the exchange every quarter, as a series. Percentages are of total shares. Each figure names the filing it was read from and the date it was filed.
| Holder | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-22 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter and promoter group | 55.01 | 54.61 | 54.60 | 54.60 | 54.60 | 53.92 | 53.91 | 53.91 | 53.79 | 0.53 | 0.53 | 0.53 | 0.53 | 0.53 |
| Domestic institutions | 8.63 | 9.14 | 9.56 | 9.69 | 12.71 | 12.89 | 13.17 | 16.08 | 17.91 | 0.18 | 0.19 | 0.19 | 0.21 | 0.22 |
| Mutual funds | — | — | — | — | — | — | — | — | 15.04 | 0.16 | 0.17 | 0.17 | 0.19 | 0.19 |
| Insurance companies | 2.41 | 2.61 | 2.73 | 2.30 | 2.84 | 2.54 | 2.53 | 2.75 | 2.40 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
| Foreign institutions | 23.27 | 24.36 | 25.35 | 26.15 | 25.42 | 26.82 | 26.82 | 23.91 | 21.68 | 0.22 | 0.21 | 0.20 | 0.17 | 0.17 |
| Government | — | — | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Public | 44.55 | 44.98 | 45.03 | 45.08 | 45.10 | 45.75 | 45.81 | 45.83 | 45.82 | 0.46 | 0.46 | 0.46 | 0.46 | 0.46 |
| Non-institutional | 12.66 | 11.48 | 10.12 | 9.24 | 6.96 | 6.04 | 5.82 | 5.84 | 6.23 | 0.06 | 0.07 | 0.07 | 0.08 | 0.07 |
| Shares outstanding | 83408877 | 83469852 | 83477852 | 83477852 | 83480352 | 83574252 | 83587735 | 83591735 | 83775510 | 83775510 | 167551020 | 167551020 | 167555020 | 167637770 |
Related parties
Transactions with related parties as disclosed to the exchange for the period ending 2024-09-30, by counterparty, largest first. Amounts are as filed. Each row names the filing and the date it was filed.
| Counterparty | Relationship | Type | Amount in the period | Transactions |
|---|---|---|---|---|
| (Hony) Brig. Dr. Arvind Lal | Key Management Personnel and its r | Dividend paid, Remuneration | 329,490,000.00 | 2 |
| Dr. Vandana Lal | Key Management Personnel and its r | Any other transaction, Dividend paid, Remuneration | 206,290,000.00 | 3 |
| Dr. Lal PathLabs Limited Group Gratuity Trust (formerly Dr. | Entities with joint control or sig | Any other transaction | 200,000,000.00 | 2 |
| Dr. Lal Pathlabs Limited Employee Welfare Trust | Entities with joint control or sig | Any other transaction | 193,850,000.00 | 1 |
| Dr. Om Prakash Manchanda | Key Management Personnel and its r | Any other transaction, Dividend paid, Remuneration | 144,600,000.00 | 3 |
| Lal Pathlabs Foundation (formerly Dr. Lal PathLabs Welfare T | Entities with joint control or sig | Any other transaction | 45,610,000.00 | 5 |
| Dr. Lal PathLabs Nepal Private Limited | Foreign Subsidiary | Sale of goods or services | 27,650,000.00 | 1 |
| Suburban Diagnostics India Private Limited | Wholly Owned Subsidiary | Purchase of goods or services, Sale of goods or serv | 23,290,000.00 | 3 |
| Ved Prakash Goel | Key Management Personnel and its r | Any other transaction, Dividend paid, Remuneration | 23,240,000.00 | 3 |
| Dr. Archana Lal Erdmann | Key Management Personnel and its r | Any other transaction, Dividend paid | 23,030,000.00 | 2 |
| Anjaneya Lal | Key Management Personnel and its r | Dividend paid, Remuneration | 22,090,000.00 | 2 |
| Centrapath Labs Private Limited | Subsidairy | Purchase of goods or services, Sale of goods or serv | 20,750,000.00 | 2 |
| Shankha banerjee | Key Management Personnel and its r | Remuneration | 18,250,000.00 | 1 |
| Dr. Lal PathLabs Bangladesh Private Limited | Foreign Subsidiary | Sale of goods or services | 17,010,000.00 | 1 |
| APRL PathLabs Private Limited | Subsidairy | Purchase of goods or services, Sale of goods or serv | 11,890,000.00 | 3 |
What management said
Every earnings call we hold for this company, read in full. Prepared remarks are separated from the question-and-answer session and every paragraph names who said it and on which page. These are management’s own words, not filed figures.
| Date | Quarter | Who spoke | |
|---|---|---|---|
| 2026-07-30 | Q1FY27 | Read the call | |
| 2026-02-03 | Q3FY26 | Read the call | |
| 2025-11-06 | Q2FY26 | Read the call | |
| 2025-08-05 | Q1FY26 | Read the call | |
| 2025-05-01 | Q4FY25 | Read the call | |
| 2025-02-03 | Q3FY25 | Read the call | |
| 2024-10-28 | H1FY25 | Read the call | |
| 2024-08-13 | Q1FY25 | Read the call | |
| 2024-05-15 | Q4FY24 | Read the call | |
| 2024-02-07 | Read the call | ||
| 2023-11-08 | H1FY24 | Read the call | |
| 2023-08-02 | Q1FY24 | Read the call | |
| 2023-05-16 | FYFY23 | Read the call | |
| 2023-02-08 | Q3FY23 | Read the call | |
| 2022-11-14 | Q2FY23 | Read the call | |
| 2022-08-03 | Q1FY23 | Read the call | |
| 2022-05-23 | Q4FY22 | Read the call | |
| 2022-02-25 | Q3FY22 | Read the call | |
| 2021-11-15 | Q2FY22 | Read the call | |
| 2021-08-11 | Q1FY22 | Read the call | |
| 2021-06-08 | Q4FY21 | Read the call | |
| 2021-02-09 | Read the call | ||
| 2020-11-24 | H1FY21 | Read the call | |
| 2020-08-17 | Q1FY21 | Read the call | |
| 2020-06-09 | Q4FY20 | Read the call | |
| 2019-08-29 | Q1FY20 | Read the call | |
| 2019-08-28 | Q1FY20 | Read the call | |
| 2019-06-19 | FYFY19 | Read the call | |
| 2019-03-07 | Q3FY19 | Read the call |
What they said about it, quarter by quarter
| Topic | Q3FY23 | Q3FY25 | Q3FY26 | Q4FY20 | Q4FY21 | Q4FY22 | Q4FY24 | Q4FY25 |
|---|---|---|---|---|---|---|---|---|
| Capex | — | These are similar because there is not much CAPEX which is done in terms of newer investment. | Can you help us with the CAPEX number for the current quarter? | — | — | — | So, right now, our business model is to actually play more in pathology, which is more hub-and-spoke model, low capex, high ROCE v/s, let's say, take … | And my second question is with respect to the CAPEX. |
| Capital allocation | — | Net cash as on 31st December 2024 is Rs.1,123 crore. • At last, I am pleased to share that the Board of Directors of the company have approved a Third… | And also acquisition, small, big task, is that a possibility you see in the current environment? | Let us say next five years or something as you expand geographically and other areas, one is the natural acquisition of the customer, and the other is… | — | Let's take a three-year, five-year outlook because when you did the call for the merger, when you did call out this acquisition, you clearly said that… | And a lot of these patient acquisition activities, I think which Om mentioned, as well as some other future improvements that we have done, should ens… | Because we were writing part of the acquisition cost through amortizing it through P&L. |
| Costs | — | If you can take us through the dynamics in terms of volumes, Swasthfit mix and you have raw material prices, currency, etc., how should we think about… | — | Clearly, the raw material consumable cost that you see, revenue share is the variable cost, manpower is a bit of a semi-variable because there is a bi… | — | — | — | — |
| Debt and cash | — | — | — | Because otherwise, those guys might see us as funding their working capital. | — | — | — | — |
| Demand | So, they are expecting collection to be done near them, which could be in the format of a collection center or a home collection, etc., See, in the pa… | I think Bundle Testing is a phenomena which is now across the industry, and I think to a certain extent the promotions done by the online competitors … | — | We have seen only a mildly similar shocks in the past post listing for you which is demonetization and demand there seem to come back in a couple of q… | The business has a sudden spike in demand, we really couldn't catch up to the pace to catch up with the demand because many of our own employees also … | I think disproportionate focus is on the demand side, on building franchisee network. | No, I think the way you should look at it is the following; because having more labs technically is not a demand generation activity. | — |
| Guidance | — | And you are still on the old tax rate and any plans to move into the new tax rate and what should we expect in terms of an effective tax rate in the y… | Any full year guidance incorporating these high investments in radiology and even Sovaaka preventive wellness program? | So, I think immediate reaction to your question is it will be difficult to make up through a price increase on shortfall that we expect in the year. | Assuming that the things become normal sooner, can we expect the growth can actually be very high kind, like we have seen in Q4 for FY22? | And, secondly, I mean, generally in the past, we used to guide for, let's say 14%, 15% kind of base business growth. | My first question is on our guidance for next year. | Are you starting to see traction there and in FY26 can we expect to see NCR volume growth at least better? |
| Margin | Sir, on Suburban, the patient count for the quarter, the revenue and EBITDA, if you can provide? | This time I want to share about as to how we navigated our business without the price increase and still delivered better than last year revenue and E… | I think if you see H1 margin was higher this quarter. | Second question, Ved, is on the gross margin. | At current prices which have already been reduced significantly, is it like at EBITDA margin level, is that business diluted for the overall company l… | But my sense is also this intensity has gone up primarily because of these two years of very high operating leverage both small and large players have… | However, we've been able to sustain our EBITDA profile. | But I just want to understand how we should look at margin for FY26. Thank you. |
| People | — | — | My first question is on the extent of utilization of both the Mumbai and Bangalore reference labs. | We are relooking at hiring, etc., and we are also looking at some ways and means of redeploying our resources as this COVID is a new work and we redep… | — | — | — | The reason why I ask is this, our lab utilizations surely seem to be going up. |
| Pricing | In terms of pricing, etc., that's the market forces will decide, because you can't command prices the way you want them. | The growth is delivered through sample volume growth and mix improvement and does not have any price increase benefit. | But yes, of course, if dollar trajectory is upwards like this, then definitely we have to review our pricing again. | So what we have seen in your pricing profile over the last two-three years is that there has not been any kind of pricing hikes that have been underta… | Earlier my thought was we were picky in terms of where we want to do the RT-PCR in COVID business based on state pricing because they were deviating, … | And secondly, you saw the dynamic pricing, virtually every month the prices were coming down. | But I think the level playing field is becoming a little more, a little better compared to, I think, some of the players have already taken price incr… | I think, you know, this year, the year that has gone by, we had started the year saying that we would like to do slightly better than the previous yea… |
| Revenue growth | So, 99.9%, our efforts are on driving top line. | I am pleased to share with you that Delhi NCR recorded double-digit revenue growth for the second successive quarter. | I think on the first one in terms of revenue, I think we have been consistent in trying to say that right now we are focusing only on organic revenue … | So we are very clearly focused on reviving non-COVID business because we know that COVID business is a temporary opportunity, it also exists primarily… | — | — | I think our Q4 revenue growth is inching towards double digits. | Yes, I think, you know, what we were saying in maybe one quarter back that we were mostly talking about NCR revenue growth and since we are not taking… |